Abstract: The present disclosure relates to a monoclonal antibody specifically binding to cathepsin Z, and a use thereof. The monoclonal antibody specifically binding to cathepsin Z of the present disclosure, or an antigen-binding fragment thereof specifically binds to CtsZ, and thus can inhibit in vivo tumorigenesis of cancer in which CtsZ is overexpressed, particularly, brain cancer, more particularly, mesenchymal brain cancer stem cells. Therefore, the present disclosure can be usefully used for treatment of patients with cancer in which CtsZ is overexpressed, specifically patients with mesenchymal brain cancer, more specifically patients with glioblastoma. In addition, the monoclonal antibody of the present disclosure or an antigen-binding fragment thereof, which specifically binds to cathepsin Z, allows diagnosis of cancer in which CtsZ is overexpressed, specifically brain cancer, more specifically glioblastoma.

Abstract: The present disclosure relates to a polypeptide containing a self-assembling domain, a fusion protein containing the polypeptide, a nucleic acid molecule encoding the same, or a composition containing the polypeptide, fusion protein or nucleic acid molecule. The fusion protein or composition of the present disclosure can be combined or loaded with various drug moieties (proteins, antibody fragments, etc.) depending on desired purposes into a module form and can be combined through self-assembly to achieve improved binding to a target and/or increased drug activity.